Información del artículo
El Texto completo está disponible en PDF
References
[1.]
M.C. Hogan, K.J. Foreman, M. Naghavi.
Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards Millennium Development Goal 5.
Lancet, 375 (2010), pp. 1609-1623
[2.]
C. Ronsmans, W.J. Graham.
Maternal mortality: who, when, where, and why.
Lancet, 368 (2006), pp. 1189-1200
[3.]
WHO Recommendations for the prevention of postpartum haemorrhage.
World Health Organisation, (2007),
[4.]
S. Okamoto, A. Hijikata-Okunomiya, K. Wanaka, Y. Okada, U. Okamoto.
Enzyme controlling medicines: introduction.
Semin Thromb Hemost, 23 (1997), pp. 493-501
[5.]
DA Henry, PA Carless, AJ Moxey.
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
Cochrane Database Syst Rev, 4 (2007),
[6.]
CRASH-2: tranexamic acid and trauma patients. Executive Summary.
[7.]
CRASH-2 trial collaborators.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Lancet, 376 (2010), pp. 23-32
[8.]
P. Ferrer, I. Roberts, E. Sydenham, K. Blackhall, H. Shakur.
Anti-fi brinolytic agents in postpartum haemorrhage: a systematic review.
BMC Pregnancy Childbirth, 9 (2009), pp. 29
[9.]
H. Shakur, D. Elbourne, M. Gulmezoglu.
The WOMAN Trial (World Maternal Antifi brinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
Trials, 11 (2010), pp. 40
Copyright © 2010. Revista Colombiana de Anestesiología
Opciones de artículo